Rigel Pharmaceuticals, Inc.
RIGL
$41.50
-$0.49-1.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 787.33% | 287.75% | 169.69% | 115.89% | 62.32% |
| Total Depreciation and Amortization | 51.81% | 89.85% | 79.97% | 55.98% | 35.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -376.43% | -6.44% | 35.05% | 1.38% | -10.62% |
| Change in Net Operating Assets | 52.60% | -1,121.34% | -98.39% | 31.56% | -18.93% |
| Cash from Operations | 634.74% | 632.64% | 647.99% | 150.10% | 63.09% |
| Capital Expenditure | -- | -- | -- | 86.30% | -- |
| Sale of Property, Plant, and Equipment | -25.76% | -25.76% | -62.16% | -72.75% | -82.54% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,437.31% | -38.91% | 189.29% | -61.23% | -90.51% |
| Cash from Investing | -1,380.18% | -41.46% | 196.11% | -61.42% | -90.25% |
| Total Debt Issued | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 202.03% | 107.48% | 87.23% | -14.20% | -26.60% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -123.06% | -149.81% | -416.91% | -156.07% | 47.41% |
| Cash from Financing | -104.96% | -164.53% | -163.38% | -179.95% | -116.45% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 236.46% | 237.39% | 187.74% | -59.62% | -159.04% |